ASSESSING THE IMPACT OF PHARMACOGENOMICS ON DRUG PRESCRIBING PATTERNS IN CHRONIC DISEASE MANAGEMENT
DOI:
https://doi.org/10.62019/xtdsr651Keywords:
Pharmacogenomics, Genetic testing, Adverse drug effects, Healthcare policy, Clinical implementationAbstract
Background: Pharmacogenomics has emerged as a useful tool in tailoring drug therapies, particularly in managing chronic diseases, where safety and efficacy over the long term are critical.
Objective: This study aimed to establish pharmacogenomics' effect on drug prescribing practices among medical practitioners managing chronic illnesses.
Methodology: A cross-sectional survey was performed through a questionnaire structured in the physicians', pharmacists', and healthcare practitioners' practicing clinics of Pakistan. Data were examined through SPSS version 26.0 utilizing descriptive and inferential statistical analysis.
Results: The results indicated that while 76.2% of the participants knew about pharmacogenomics, 45.5% of them reported using it in prescribing. A clear majority recognized that it could restrict adverse drug effects (69.4%) and enhance therapeutic efficacy (72.8%), but asserted that they encountered barriers of training and infrastructure that limited its use.
Conclusion: This study concludes that although pharmacogenomics is more familiar with its benefits in chronic disease management, its use in routine practice remains limited, which emphasizes the role of guideline-based implementation strategies, clinician education, and policy efforts.
Downloads
Downloads
Published
Versions
- 2025-05-05 (2)
- 2025-05-05 (1)